Stefan Riedel1,2, Divya Vijayakumar3, Gretchen Berg1, Anthony D Kang1,4, Kenneth P Smith1,2, James E Kirby1,2. 1. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Northeastern University, Boston, MA, USA. 4. Department of Pathology and Ancillary Laboratory Services, Carl R. Darnall Army Medical Center, Fort Hood, TX, USA.
Abstract
BACKGROUND: The emergence of Neisseria gonorrhoeae resistant to all currently available antimicrobial therapies poses a dire public health threat. New antimicrobial agents with activity against N. gonorrhoeae are urgently needed. Apramycin is an aminocyclitol aminoglycoside with broad-spectrum in vitro activity against MDR Gram-negative pathogens and Staphylococcus aureus. However, its activity against N. gonorrhoeae has not been described. OBJECTIVES: The activity spectrum of apramycin against a collection of MDR N. gonorrhoeae was assessed. Isolates tested included those susceptible and resistant to the structurally distinct aminocyclitol, spectinomycin. RESULTS: The modal MICs for apramycin and spectinomycin were 16 mg/L and 32 mg/L, respectively. The epidemiological cut-off (ECOFF) for apramycin was 64 mg/L. No strains among 77 tested had an MIC above this ECOFF, suggesting very low levels of acquired apramycin resistance. In time-kill analysis, apramycin demonstrated rapid bactericidal activity comparable to that of spectinomycin. CONCLUSIONS: Apramycin has broad-spectrum, rapidly bactericidal activity against N. gonorrhoeae. Future pharmacokinetic and pharmacodynamic studies will be needed to determine whether apramycin and/or apramycin derivatives hold promise as new therapeutics for N. gonorrhoeae infection.
BACKGROUND: The emergence of Neisseria gonorrhoeae resistant to all currently available antimicrobial therapies poses a dire public health threat. New antimicrobial agents with activity against N. gonorrhoeae are urgently needed. Apramycin is an aminocyclitol aminoglycoside with broad-spectrum in vitro activity against MDR Gram-negative pathogens and Staphylococcus aureus. However, its activity against N. gonorrhoeae has not been described. OBJECTIVES: The activity spectrum of apramycin against a collection of MDR N. gonorrhoeae was assessed. Isolates tested included those susceptible and resistant to the structurally distinct aminocyclitol, spectinomycin. RESULTS: The modal MICs for apramycin and spectinomycin were 16 mg/L and 32 mg/L, respectively. The epidemiological cut-off (ECOFF) for apramycin was 64 mg/L. No strains among 77 tested had an MIC above this ECOFF, suggesting very low levels of acquired apramycin resistance. In time-kill analysis, apramycin demonstrated rapid bactericidal activity comparable to that of spectinomycin. CONCLUSIONS:Apramycin has broad-spectrum, rapidly bactericidal activity against N. gonorrhoeae. Future pharmacokinetic and pharmacodynamic studies will be needed to determine whether apramycin and/or apramycin derivatives hold promise as new therapeutics for N. gonorrhoeae infection.
Authors: Robert A Giacobbe; Michael D Huband; Boudewijn L M deJonge; Patricia A Bradford Journal: Diagn Microbiol Infect Dis Date: 2016-03-08 Impact factor: 2.803
Authors: Andrew G McArthur; Nicholas Waglechner; Fazmin Nizam; Austin Yan; Marisa A Azad; Alison J Baylay; Kirandeep Bhullar; Marc J Canova; Gianfranco De Pascale; Linda Ejim; Lindsay Kalan; Andrew M King; Kalinka Koteva; Mariya Morar; Michael R Mulvey; Jonathan S O'Brien; Andrew C Pawlowski; Laura J V Piddock; Peter Spanogiannopoulos; Arlene D Sutherland; Irene Tang; Patricia L Taylor; Maulik Thaker; Wenliang Wang; Marie Yan; Tennison Yu; Gerard D Wright Journal: Antimicrob Agents Chemother Date: 2013-05-06 Impact factor: 5.191
Authors: Lillian B Brown; Robert Krysiak; Gift Kamanga; Clemente Mapanje; Happiness Kanyamula; Blessings Banda; Chisale Mhango; Mariah Hoffman; Debbie Kamwendo; Marcia Hobbs; Mina C Hosseinipour; Francis Martinson; Myron S Cohen; Irving F Hoffman Journal: Sex Transm Dis Date: 2010-03 Impact factor: 2.830
Authors: Robert D Kirkcaldy; Hillard S Weinstock; Page C Moore; Susan S Philip; Harold C Wiesenfeld; John R Papp; Peter R Kerndt; Shacondra Johnson; Khalil G Ghanem; Edward W Hook Journal: Clin Infect Dis Date: 2014-07-16 Impact factor: 9.079
Authors: Tanja Matt; Chyan Leong Ng; Kathrin Lang; Su-Hua Sha; Rashid Akbergenov; Dmitri Shcherbakov; Martin Meyer; Stefan Duscha; Jing Xie; Srinivas R Dubbaka; Déborah Perez-Fernandez; Andrea Vasella; V Ramakrishnan; Jochen Schacht; Erik C Böttger Journal: Proc Natl Acad Sci U S A Date: 2012-06-14 Impact factor: 11.205
Authors: Jonathan C K Quirke; Parasuraman Rajasekaran; Vikram A Sarpe; Amr Sonousi; Ivan Osinnii; Marina Gysin; Klara Haldimann; Qiao-Jun Fang; Dimitri Shcherbakov; Sven N Hobbie; Su-Hua Sha; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich Journal: J Am Chem Soc Date: 2019-12-17 Impact factor: 15.419
Authors: Kenneth P Smith; Matthew G Dowgiallo; Lucius Chiaraviglio; Prakash Parvatkar; Chungsik Kim; Roman Manetsch; James E Kirby Journal: SLAS Discov Date: 2019-07-03 Impact factor: 3.341